Evidence map›Paper›PMID 24952269›Full record

ArticleClinical & experimental metastasis2014

Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells.

Manohar C Dange, Nithya Srinivasan, Shyam K More, Sanjay M Bane, Archana Upadhya, Arvind D Ingle, Rajiv P Gude, Rabindranath Mukhopadhyaya, Rajiv D Kalraiya

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01681823 (Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01681823 phase2completednot on this map

Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA

TypeinterventionalSponsorEcoNugenicsRan2013 to 2020Enrolled60ConditionsProstatic NeoplasmsArmsPectaSol-C Modified Citrus Pectin (MCP)
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Core-Fucosylated Tetra-AntennaryInternational journal of molecular sciences · 2019
    Article
  6. The emerging role of galectins in high-fatality cancers.Cellular and molecular life sciences : CMLS · 2018
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Manohar C DangeKalraiya Lab, KS 131, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Sector 22, Kharghar, Navi Mumbai, 410210, India.
Nithya Srinivasan
Shyam K More
Sanjay M Bane
Archana Upadhya
Arvind D Ingle
Rajiv P Gude
Rabindranath Mukhopadhyaya
Rajiv D Kalraiya
Tata Memorial Hospital · INAdvanced Centre for Treatment, Research and Education in Cancer · INNarsee Monjee Institute of Management Studies · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interactions between molecules on the surface of tumor cells and those on the target organ endothelium play an important role in their arrest in an organ. Galectin-3 on the lung endothelium and high affinity ligands poly-N-acetyllactosamine (polyLacNAc) on N-oligosaccharides on melanoma cells facilitate such interactions. However, to extravasate and colonize an organ the cells must stabilize these interactions by spreading to retract endothelium, degrade exposed basement membrane (BM) and move into parenchyma and proliferate. Here, we show that galectin-3 is expressed on all the major compartments of the lungs and participates in not just promoting adhesion but also in spreading. We for the first time demonstrate that both soluble and immobilized galectin-3 induce secretion of MMP-9 required to breach vascular BM. Further, we show that immobilized galectin-3 is used as traction for the movement of cells. Downregulation of galactosyltransferases-I and -V resulted in significant loss in expression of polyLacNAc and thus reduced binding of galectin-3. This was accompanied with a loss in adhesion, spreading, MMP-9 secretion and motility of the cells on galectin-3 and thus their metastasis to lungs. Metastasis could also be inhibited by blocking surface polyLacNAc by pre-incubating cells with truncated galectin-3 (which lacked oligomerization domain) or by feeding mice with modified citrus pectin in drinking water. Overall, these results unequivocally show that polyLacNAc on melanoma cells and galectin-3 on the lungs play a critical role in arrest and extravasation of cells in the lungs and strategies that target these interactions inhibit lung metastasis.

Indexed as

AnimalsBase SequenceBlotting, WesternCell AdhesionCell Line, TumorDNA PrimersFlow CytometryGalectin 3LigandsLungMelanoma, ExperimentalMiceReal-Time Polymerase Chain ReactionDNA PrimersGalectin 3Ligands

Identifiers

PMID24952269
OpenAlexW2029920223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.